Open an account

Curis

CRIS · NASDAQ

$0.3996+$0.0256 (+6.84%)TodayMarket closed ·
Prev close $0.374

About CRIS

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Employees
24
Headquarters
Lexington, Massachusetts
Listed
Aug 1, 2000
Sector
Health Care
Industry
Biotechnology
Website
curis.com

CRIS key statistics

Market cap
835.19K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
271.77K
Volume
543
Open price
$0.3655
High today
$0.41
Low today
$0.3655
52 Week high
$33.60
52 Week low
$0.325

Curis (CRIS) at a glance

Curis (CRIS) last traded at $0.3996, with a market cap of 835.19K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3655 and $0.41. The current price is 9.3% above the day's low and 2.5% below its high.

Volume so far is 543 shares, below the average of 271.77K shares a day.

Over the past year Curis has ranged from $0.325 to $33.60, and now sits 0% of the way up that range.

Curis met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$4.02 per share against an estimate of -$8.00.

The average analyst price target is $43.52, 10790.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $43.52
Low
$20.20
Now
$0.3996
High
$68.25

CRIS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 25.4% on average.

  1. Q3 FY24: reported -$34.00 per share against an estimate of -$23.87
  2. Q4 FY24: reported -$25.00 per share against an estimate of -$27.74
  3. Q1 FY25: reported -$25.00 per share against an estimate of -$24.23
  4. Q2 FY25: reported -$13.60 per share against an estimate of -$18.16
  5. Q3 FY25: reported -$9.80 per share against an estimate of -$11.79
  6. Q4 FY25: reported -$10.00 per share against an estimate of -$9.18
  7. Q1 FY26: reported -$25.00 per share against an estimate of -$8.16
  8. Q2 FY26: reported -$4.02 per share against an estimate of -$8.00

CRIS news

  • Avi Kapoor

    Dow Surges 250 Points; M&T Bank Posts Upbeat Q3 Earnings

  • Press releasePRNewswire

    Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releasePRNewswire

    Curis, Inc. Announces Pricing of $5.6 Million Public Offering

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releasePRNewswire

    Curis Doses First Five Patients in TakeAim CLL Study

Similar companies

Companies in the same industry as Curis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.